38.26

2.25% 0.8477

Urogen Pharma Ltd (URGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$37.41

Offen:

$37.5

24-Stunden-Volumen:

538.59K

Relative Volume:

0.69

Marktkapitalisierung:

$1.87B

Einnahmen:

$109.79M

Nettoeinkommen (Verlust:

$-153.49M

KGV:

-11.92

EPS:

-3.2098

Netto-Cashflow:

$-172.59M

1W Leistung:

+3.94%

1M Leistung:

+42.46%

6M Leistung:

+65.30%

1J Leistung:

+183.54%

1-Tages-Spanne:

$36.67

$39.12

1-Wochen-Bereich:

$36.67

$39.59

52-Wochen-Spanne:

$13.26

$39.59

Urogen Pharma Ltd Stock (URGN) Company Profile

Firmenname

Urogen Pharma Ltd

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

972 9 770 7601

Adresse

9 HA'TA'ASIYA ST, RA'ANANA

Mitarbeiter

291

Twitter

@UroGenPharma

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

URGN's Discussions on Twitter

Compare URGN vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
URGN Urogen Pharma Ltd	38.30	1.85B	109.79M	-153.49M	-172.59M	-3.2098
VRTX Vertex Pharmaceuticals Inc	523.88	134.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.87	68.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	921.67	58.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	320.22	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	191.59	40.23B	742.00K	-1.37B	-1.07B	-7.0731

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-10	Eingeleitet	Jefferies	Buy
2025-08-19	Eingeleitet	Piper Sandler	Overweight
2025-06-16	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-05-22	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-04-16	Eingeleitet	Scotiabank	Sector Outperform
2025-02-19	Fortgesetzt	Ladenburg Thalmann	Buy
2024-08-22	Eingeleitet	Guggenheim	Buy
2023-02-08	Herabstufung	Jefferies	Buy → Hold
2022-04-27	Eingeleitet	Berenberg	Buy
2020-04-16	Bestätigt	H.C. Wainwright	Buy
2020-04-13	Bestätigt	H.C. Wainwright	Buy
2020-01-09	Eingeleitet	National Securities	Neutral
2019-05-30	Eingeleitet	JP Morgan	Neutral
2019-05-29	Eingeleitet	Goldman	Neutral
2019-01-29	Eingeleitet	H.C. Wainwright	Buy
2018-11-08	Fortgesetzt	Jefferies	Buy
2018-04-04	Hochstufung	Raymond James	Mkt Perform → Outperform
2018-01-02	Eingeleitet	Ladenburg Thalmann	Buy
2017-11-15	Bestätigt	Oppenheimer	Outperform
2017-11-15	Herabstufung	Raymond James	Outperform → Mkt Perform

Alle ansehen

Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten

Jul 02, 2026

UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar - Sahm

Jul 02, 2026

Jul 01, 2026

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? - The Motley Fool

Jul 01, 2026

Jun 30, 2026

UroGen Pharma (URGN) Surges 4.24% as Shares Approach Key Resistance LevelCombination Correction - dars.gov.et

Jun 30, 2026

Jun 29, 2026

UroGen Pharma stock consolidates below 52-week high amid sustained bullish momentum - Traders Union

Jun 29, 2026

UroGen Pharma edges higher to $34.88 as leadership highlights integrity focus, UroGen Pharma - Traders Union

Jun 29, 2026

Urogen Pharma stock hits 52-week high at 36.12 USD - Investing.com

Jun 29, 2026

Urogen Pharma stock hits 52-week high at 36.12 USD By Investing.com - Investing.com India

Jun 29, 2026

Enterprise value to revenue forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView

Jun 27, 2026

Price to earnings forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView

Jun 27, 2026

Enterprise value to EBIT forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView

Jun 27, 2026

Enterprise value to EBIT forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView

Jun 27, 2026